ROCKVILLE, Md.--(BUSINESS WIRE)--Neuralstem, Inc. (NYSE Amex: CUR) announced today that it has entered into a sponsored research agreement with the China Medical University & Hospital of Taiwan, in Taichung, Taiwan, to prepare for a human clinical trial using Neuralstem’s human spinal cord neural stem cells to treat stroke patients. The therapy will focus on patients whose post-stroke symptoms, including complete or partial paralysis, have stopped improving more than six months after an ischemic stroke. Ischemic stroke, caused by a blockage in a vessel supplying blood to the brain, is the most common type of stroke and affects more than 400,000 people in the United States yearly. There are about 6.5 million stroke survivors in the U.S. alone. “We are excited to be moving forward in treating stroke with our cells,” said... [read full story]
